Literature DB >> 26521067

Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism.

Angela N Henderson-Redmond1, Matthew B Yuill2, Tammy E Lowe3, Aaron M Kline1, Michael L Zee1, Josée Guindon4, Daniel J Morgan5.   

Abstract

The rewarding and antinociceptive effects of opioids are mediated through the mu-opioid receptor. The A118G single nucleotide polymorphism in this receptor has been implicated in drug addiction and differences in pain response. Clinical and preclinical studies have found that the G allele is associated with increased heroin reward and self-administration, elevated post-operative pain, and reduced analgesic responsiveness to opioids. Male and female mice homozygous for the "humanized" 118AA or 118GG alleles were evaluated to test the hypothesis that 118GG mice are less sensitive to the rewarding and antinociceptive effects of morphine. We found that 118AA and 118GG mice of both genders developed conditioned place preference for morphine. All mice developed tolerance to the antinociceptive and hypothermic effects of morphine. However, morphine tolerance was not different between AA and GG mice. We also examined sensitivity to the antinociceptive and hypothermic effects of cumulative morphine doses. We found that 118GG mice show reduced hypothermic and antinociceptive responses on the hotplate for 10mg/kg morphine. Finally, we examined basal pain response and morphine-induced antinociception in the formalin test for inflammatory pain. We found no gender or genotype differences in either basal pain response or morphine-induced antinociception in the formalin test. Our data suggests that homozygous expression of the GG allele in mice blunts morphine-induced hypothermia and hotplate antinociception but does not alter morphine CPP, morphine tolerance, or basal inflammatory pain response.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  A118G; Antinociception; Formalin test; MOR; Morphine reward; Morphine tolerance; Pain; mu Opioid receptor

Mesh:

Substances:

Year:  2015        PMID: 26521067      PMCID: PMC4848164          DOI: 10.1016/j.brainresbull.2015.10.007

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  46 in total

1.  Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.

Authors:  J Gelernter; H Kranzler; J Cubells
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

2.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

3.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

4.  Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty.

Authors:  W-Y Chou; L-C Yang; H-F Lu; J-Y Ko; C-H Wang; S-H Lin; T-H Lee; A Concejero; C-J Hsu
Journal:  Acta Anaesthesiol Scand       Date:  2006-08       Impact factor: 2.105

5.  The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans.

Authors:  Roger B Fillingim; Lee Kaplan; Roland Staud; Timothy J Ness; Toni L Glover; Claudia M Campbell; Jeffrey S Mogil; Margaret R Wallace
Journal:  J Pain       Date:  2005-03       Impact factor: 5.820

6.  Cocaine-induced suppression of saccharin intake and morphine modulation of Ca²⁺ channel currents in sensory neurons of OPRM1 A118G mice.

Authors:  Christopher S Freet; Sarah M Ballard; Danielle N Alexander; Taylor A Cox; Caesar G Imperio; Nnaemeka Anosike; Alyssa B Carter; Saifeldin Mahmoud; Victor Ruiz-Velasco; Patricia S Grigson
Journal:  Physiol Behav       Date:  2014-11-18

7.  Polymorphism in the µ-opioid receptor gene (OPRM1) modulates neural processing of physical pain, social rejection and error processing.

Authors:  M Bonenberger; P L Plener; R C Groschwitz; G Grön; B Abler
Journal:  Exp Brain Res       Date:  2015-05-28       Impact factor: 1.972

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 9.  OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis.

Authors:  In Cheol Hwang; Ji-Young Park; Seung-Kwon Myung; Hong Yup Ahn; Ken-ichi Fukuda; Qin Liao
Journal:  Anesthesiology       Date:  2014-10       Impact factor: 7.892

10.  The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor.

Authors:  Thomas Kroslak; K Steven Laforge; Robert J Gianotti; Ann Ho; David A Nielsen; Mary Jeanne Kreek
Journal:  J Neurochem       Date:  2007-10       Impact factor: 5.372

View more
  8 in total

1.  Convergent Balancing Selection on the Mu-Opioid Receptor in Primates.

Authors:  Carolyn G Sweeney; Juliette M Rando; Helen N Panas; Gregory M Miller; Donna M Platt; Eric J Vallender
Journal:  Mol Biol Evol       Date:  2017-07-01       Impact factor: 16.240

2.  Heroin-induced suppression of saccharin intake in OPRM1 A118G mice.

Authors:  Christopher S Freet; Danielle N Alexander; Caesar G Imperio; Victor Ruiz-Velasco; Patricia S Grigson
Journal:  Brain Res Bull       Date:  2017-09-20       Impact factor: 4.077

3.  c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.

Authors:  Angela N Henderson-Redmond; Caitlin M Nealon; Brian J Davis; Matthew B Yuill; Diana E Sepulveda; Henry L Blanton; Mary K Piscura; Michael L Zee; Chris P Haskins; David J Marcus; Ken Mackie; Josée Guindon; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-11-20       Impact factor: 5.250

4.  Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.

Authors:  Matthew B Yuill; David E Hale; Josée Guindon; Daniel J Morgan
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

5.  Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.

Authors:  Ziad Saad; Derrek Hibar; Maggie Fedgchin; Vanina Popova; Maura L Furey; Jaskaran B Singh; Hartmuth Kolb; Wayne C Drevets; Guang Chen
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

6.  Prefrontal Cortex Response to Prenatal Insult and Postnatal Opioid Exposure.

Authors:  Haley E Rymut; Laurie A Rund; Bruce R Southey; Rodney W Johnson; Jonathan V Sweedler; Sandra L Rodriguez-Zas
Journal:  Genes (Basel)       Date:  2022-07-30       Impact factor: 4.141

7.  Decursinol-mediated antinociception and anti-allodynia in acute and neuropathic pain models in male mice: Tolerance and receptor profiling.

Authors:  LaTaijah C Crawford; Sangyub Kim; Deepkamal Karelia; Diana E Sepulveda; Daniel J Morgan; Junxuan Lü; Angela N Henderson-Redmond
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

Review 8.  Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies.

Authors:  Xiangyi Kong; Hao Deng; Shun Gong; Theodore Alston; Yanguo Kong; Jingping Wang
Journal:  BMC Med Genet       Date:  2017-10-26       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.